Prognostic value of aberrant promoter hypermethylation of tumor-related genes in early-stage head and neck cancer

Kiyoshi Misawa; Daiki Mochizuki; Atsushi Imai; Shiori Endo; Masato Mima; Yuki Misawa; Takeharu Kanazawa; Thomas E. Carey; Hiroyuki Mineta

doi:10.18632/oncotarget.8317

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Prognostic value of aberrant promoter hypermethylation of tumor-related genes in early-stage head and neck cancer

Kiyoshi Misawa _, Daiki Mochizuki, Atsushi Imai, Shiori Endo, Masato Mima, Yuki Misawa, Takeharu Kanazawa, Thomas E. Carey and Hiroyuki Mineta

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:26087-26098. https://doi.org/10.18632/oncotarget.8317

Metrics: PDF 2072 views | HTML 2259 views | ?

Abstract

Kiyoshi Misawa1, Daiki Mochizuki1, Atsushi Imai1, Shiori Endo1, Masato Mima1, Yuki Misawa1, Takeharu Kanazawa2, Thomas E. Carey3, Hiroyuki Mineta1

1Department of Otolaryngology/Head and Neck Surgery, Hamamatsu University School of Medicine, Shizuoka, Japan

2Department of Otolaryngology/Head and Neck Surgery, Jichi Medical University, Tochigi, Japan

3Department of Otolaryngology/Head and Neck Surgery, Laboratory of Head and Neck Cancer Biology, University of Michigan, Ann Arbor, MI, USA

Correspondence to:

Kiyoshi Misawa, e-mail: [email protected]

Keywords: tumor-suppressor genes, hypermethylation, head and neck cancer, metastases, biomarker

Received: November 03, 2015 Accepted: March 11, 2016 Published: March 24, 2016

ABSTRACT

Staging and pathological grading are useful, but imperfect predictors of recurrence in head and neck squamous cell carcinoma (HNSCC). Accordingly, molecular biomarkers that predict the risk of recurrence are necessary to improve clinical outcomes. The methylation statuses of the promoters of 11 tumor-related genes (p16, RASSF1A, E-cadherin, H-cadherin, MGMT, DAPK, DCC, COL1A2, TAC1, SST, and GALR1) were analyzed in 133 HNSCC cases using quantitative methylation-specific PCR. We detected frequent methylation of p16 (44%), RASSF1A (18%), E-cadherin (53%), H-cadherin (35%), MGMT (35%), DAPK (53%), DCC (42%), COL1A2 (44%), TAC1 (61%), SST (64%), and GALR1 (44%) in HNSCC. Disease-free survival was lower in patients with 6–11 methylated genes than in those with 0–5 methylated genes (log-rank test, P = 0.001). In a multivariate Cox proportional hazards analysis, the methylation of E-cadherin, COL1A2, TAC1, and GALR1 was associated with poor survival, with hazard ratios of 4.474 (95% CI, 1.241–16.124). In a joint analysis of these four genes, patients with 2–4 methylated genes had a significantly lower survival rate than those with 0–1 methylated genes in early-stage HNSCC. Importantly, the methylation of some genes was closely related to poor prognosis in early-stage HNSCC, providing strong evidence that these hypermethylated genes are valuable biomarkers for prognostic evaluation.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8317

Publication Alerts

Research Papers:

Prognostic value of aberrant promoter hypermethylation of tumor-related genes in early-stage head and neck cancer

Abstract